Occult HBV reactivation induced by ibrutinib treatment: A case report

Acta Gastro-Enterologica Belgica

Volumn 78, Issue 4, 2015, Pages 424-426

  Ngoma, Patrick de Jésus ^a   Kabamba, Benoît ^a   Dahlqvist, Geraldine ^a   Sempoux, Christine ^a   Lanthier, Nicolas ^a   Shindano, Tony ^a   Van Den Neste, Eric ^a   Horsmans, Yves ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Chronic lymphocytic leukaemia; Hepatitis B virus; Ibrutinib; Reactivation

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BENDAMUSTINE; ENTECAVIR; HEMOGLOBIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IBRUTINIB; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHROCYTE; FATIGUE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION; LABORATORY TEST; LIVER BIOPSY; LIVER FIBROSIS; LIVER NECROSIS; LYMPHOCYTOSIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PETECHIA; SEROLOGY; SKIN BRUISING; SPLEEN SIZE; THROMBOCYTOPENIA; VIRUS REACTIVATION; VIRUS REPLICATION; COMPLICATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PATHOLOGY; VERY ELDERLY; VIRUS ACTIVATION;

AGED, 80 AND OVER; HEPATITIS B; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; PYRAZOLES; PYRIMIDINES; VIRUS ACTIVATION;

EID: 84953338747     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. YEO W., CHAN P.K., ZHONG S., HO W.M., STEINBERG J.L., TAM J.S. et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J. Med. Virol., 2000, 62: 299-307.
2. YEO W., JOHNSON P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology, 2006, 43: 209-220.
3. PAPAMICHALIS P., ALEXIOU A.B., DALEKOS M., RIGOPOULOU G.N. et al., Reactivation of resolved hepatitis B virus infection after immunosuppression : Is it time to adopt pre-emptive therapy ? Clin. Res. Hepatol. and Gastroenterol., 2012, 36: 84-93.
4. LAI G.M., YAN S.L., CHANG C.S., TSAI C.Y. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J. Gastroenterol., 2013, 19: 1318-21.
5. IKEDA K., SHIGA Y., TAKAHASHI A., KAI T., KIMURA H., TAKEYAMA K. et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk. Lymphoma, 2006, 47: 155-7.
6. O'BRIEN S., FURMAN R.R., COUTRE S.E., SHARMAN J.P., BURGER J.A., BLUM K.A. et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma : an open-label, multicentre, phase 1b/2 trial. The Lancet Oncology, 2014, 15: 48-58.
7. HOOFNAGLE J.H. Reactivation of hepatitis B. Hepatology, 2009, 49: S156-65.
8. BORENTAIN P., COLSON P., COSO D., BORIES E., CHARBONNIER A., STOPPA A. M. et al. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J Viral Hepat, 2010, 17: 807-15.
9. CAMERON F., SANFORD M. Ibrutinib: first global approval. Drugs, 2014, 74: 263-71.
10. DUBOVSKY J.A., BECKWITH K.A., NATARAJAN G., WOYACH J.A., JAGLOWSKI S., ZHONG Y. et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood, 2013, 122: 2539-49.
11. EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J. Hepatol., 2009, 50: 227-242.
12. HUI C.K., CHEUNG W.W., ZHANG H.Y., AU W.Y., YUENG Y.H., LEUNG A.Y. et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology, 2006, 131: 59-68.
13. RAIMONDO G., POLLICINO T., CACCIOLA I., SQUADRITO G. Occult hepatitis B virus infection. J. Hepatol., 2007, 46: 160-70.
14. ONOZAWA M., HASHINO S., IZUMIYAMA K., KAHATA K., CHUMA M., MORI A. et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation, 2005, 79: 616-9.